期刊文献+

hENT1 mRNA表达与非小细胞肺癌吉西他滨化疗临床预后的相关性 被引量:7

Relation of HENT1 mRNA expression with the prognosis of non-small cell lung cancer patients received gemcitabine-based chemotherapy
下载PDF
导出
摘要 目的:探讨非小细胞肺癌(NSCLC)石蜡组织中平衡型核苷转运载体(human equilibritive nucleosidetransporter 1,hENT1)mRNA表达水平与接受吉西他滨方案化疗的患者临床病理关系及预后意义。方法:采用实时荧光定量RT-PCR方法检测福尔马林固定-石蜡包埋的非小细胞肺癌组织中hENT1 mRNA表达水平,并比较其表达水平与接受吉西他滨化疗的患者临床病理及生存期之间的关系。hENT1 mRNA表达水平与非小细胞肺癌患者的临床及肿瘤病理特征无相关性。结果:hENT1 mRNA高表达组患者经含吉西他滨方案化疗后中位无进展生存期17.5月、总生存期36月,两组间无进展生存期(P=0.420)、总生存期(P=0.707)。但是从生存曲线分析,hENT1 mRNA高表达的NSCLC患者可能从吉西他滨治疗中获益,可能获得更长无进展生存期的趋势。COX多因素回归分析显示TNM分期与肺癌患者总生存期(P=0.02)、无进展生存期(P=0.008)显著相关。hENT1 mRNA表达水平与非小细胞肺癌肿瘤病理特征无相关性,可能与肿瘤恶性生物学行为无关。结论:hENT1 mRNA的表达水平可能是含吉西他滨药物化疗的NSCLC患者预后的影响因素,肿瘤组织的分期可能是影响NSCLC患者预后的独立预测因素。 Objective: To investigate the correlation of the mRNA expression levels of human equilibritive nucleoside transporter 1(hENT1) with clinicopathological parameters in patients with non-small cell lung cancer receiving gemcitabine-based chemotherapy as well as their clincal prognostic significance.Methods: The relative mRNA expression of hENT1 to the internal reference gene β-actin in formalin-fixed paraffin-embeded non-small cell lung cancer tumor specimens was measured using real-time quantitative reverse transcription polymerase chain reaction.And the relationship between hENT1 levels with clinicopathological parameters and survival in non-small cell lung cancer was studied.Results: hENT1 expression levels were detected in all tumor specimens.hENT1 expression was not related to clinicopathological parameters in non-small cell lung cancer.Though from multivariate analysis,hENT1 mRNA hypoexpression was not a significantly favorable factor for overall survival(P = 0.707),and for time to progression(P = 0.420),there was a tendency that patients with high hENT1 mRNA levels had a significant longer median time to overall survival and progression.Although from Cox proportional hazards model for survival,hENT1 mRNA hypoexpression was not a significantly favorable factor for OS and PFS,tumor lymph node matastasis was an independent predictive marker of overall survival of non-small cell lung cancer(P = 0.02).Conclusion: Intratumoral hENT1 mRNA expression level was not associated with clinicopathological parmeters,maybe a predictive marker of survival of gemcitabine-containing combination chemotherapy in non-small cell lung cancer.It can provide critical information for planning personalized chemotherapy.Tumor lymph node matastasis was an independent predictive marker of survival of non-small cell lung cancer.
出处 《现代肿瘤医学》 CAS 2012年第4期718-722,共5页 Journal of Modern Oncology
基金 江苏省卫生厅资助项目(编号:H201035)
关键词 hENT1 非小细胞肺癌 化疗 吉西他滨 hENT1 non-small cell lung cancer chemotherapy gemcitabine
  • 相关文献

参考文献12

  • 1Danesi,Altavilla,Giovannetti Rosell. Pharmacogemics of gemcitabine in non-small-cell lung cancer and other solid tumors[J].Pharmacogenomics,2009,(01):69-80.
  • 2Raphael Marechal,John R,Mackey. Human equilibrative nucleosidetransporter 1 and human concentrative nucleosidetransporter 3 predict survival after adjuvant gemcitabinetherapyin resected pancreatic adenocarcinoma[J].Clinical Cancer Research,2009,(08):2913-2919.
  • 3Daniele Santini,Bruno Vincenzi,Maria Elisabetta Fratto. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer[J].Journal of Cellular Physiology,2010.394-388.
  • 4D Santini,G Perrone,B Vincenzi. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer[J].Annals of Oncology,2008.724-728.
  • 5Hiroyuki Achiwa,Tetsuya Oguri,Shigeki Sato. Determinants of sensitivity and resistance to gemcitabine:The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in nonsmall cell lung cancer[J].Cancer Science,2004.753-757.
  • 6Ward JL,Leung GP,Toan SV. Function alanalysis of site-directed glycosylation mutants of the human equilibrative nucleosidetransporter-2[J].Archives of Biochemistry and Biophysics,2003,(01):19-26.
  • 7Garcia-Manteiga J,Molina-Arcas M,Casado FJ. Nucleoside transporter profiles in human pancreatic cancer cells:role of hcntl in 2',2'-difluoredeoxycytidine-induced cytotoxicity[J].Clinical Cancer Research,2003.5000-5008.
  • 8Ryutaro Mori,Takashi Ishikawa,Yasushi Ichikawa. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells[J].Oncology Reports,2007,(05):1201-1205.
  • 9Giovannetti E,Del Tacca M,Mey V. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine[J].Cancer Research,2006.3928-3935.
  • 10Richard Kim,Ann Tan,Kevin K.Lai. Prognostic Roles of Human Equilibrative Transporter 1 (hENT-1) and Ribonucleoside Reductase Subunit M1 (RRM1) in Resected Pancreatic Cancer[J].Cancer,2011,(14):3126-3134.

同被引文献85

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部